Abstract 4482
Background
Cancer and the adverse events of its treatment influence patients’ psychology and decrease their quality of life. The aim of this study was the investigation of the relationship between anxiety, depression and quality of life of ambulatory cancer patients undergoing chemotherapy.
Methods
This cross-sectional study was conducted in the one-day clinic of a large anticancer Hospital in Athens, Greece. Our convenience heterogeneous sample included 150 patients who received chemotherapy. Participants completed the Distress Thermometer and Problem List, the Hospital Anxiety and Depression Scale (HADS), the EORTC QLQ-C30 (version 3.0) for the assessment of Quality of life and the demographic and clinical characteristics questionnaire. Permission for the research was obtained by the ethical committee of the hospital. Data analysis was conducted by SPSS 22.0. The statistical significance level was set at p < 0.05.
Results
The mean age of the participants was 60.07±11.42 while 64% of the sample was female. The majority of patients reported worry (82.7%), fatigue (84.7%), fear (74.7%), nervousness, (51.3%) sadness (51.3%) and depression (34%). Female patients reported higher distress levels than male (p < 0,005). The participants’ educational level was found to correlate significantly with the cognitive functioning (p = 0.017) and financial impact (p = 0.026) subscales. Statistically significant positive correlations were found between HADS-anxiety and HADS-depression and symptom subscales of the EORTC QLQ-C30 questionnaire (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbances, appetite loss and financial impact). Statistically significant negative correlations were also found between HADS-anxiety and HADS-depression and the functional subscales of the EORTC QLQ-C30 questionnaire (physical, role, emotional, cognitive and social functioning).
Conclusions
Anxiety and depression have a negative influence on the quality of life of ambulatory cancer patients during chemotherapy. Nurses could play an important role in the recognition and management of these symptoms. Academics and nurse managers professionals need to enhance nurses’ knowledge and sensitivity and empower them to take an active role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Program of Postgraduate Studies in "Neurological Disorders - Evidence Based Practice", Nursing Department, University of West Attica, Athens, Greece.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract